Molecular prognostic markers in resectable colorectal liver metastases: A systematic review

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1728-1743

  Neal, C P ^a   Garcea, G ^b   Doucas, H ^a   Manson, M M ^a   Sutton, C D ^b   Dennison, A R ^b   Berry, D P ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Colorectal cancer; Liver metastasis; Metastasectomy; Prognosis; Survival

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53; TELOMERASE; THROMBOSPONDIN 1; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER RISK; CELL PROLIFERATION; COLORECTAL SURGERY; COLORECTAL TUMOR; CORRELATION ANALYSIS; HUMAN; LIVER METASTASIS; LIVER RESECTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SURGICAL TECHNIQUE;

APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; GENOMIC INSTABILITY; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PROGNOSIS; TELOMERASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 33746658649     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.056     Document Type: Article

References (183)

1. Jatzko G.R., Lisborg P.H., Stettner H.M., and Klimpfinger M.H. Hepatic resection for metastases from colorectal carcinoma - a survival analysis. Eur J Cancer 31 (1995) 41-46
2. Fegiz G., Ramacciato G., Gennari L., et al. Hepatic resections for colorectal metastases: the Italian multicenter experience. J Surg Oncol 2 (1991) S144-S154
3. Taylor M., Forster J., Langer B., Taylor B.R., Greig P.D., and Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 173 (1997) 467-471
4. Yamamoto J., Shimada K., Kosuge T., Yamasaki S., Sakamoto M., and Fukuda H. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86 (1999) 332-337
5. Hughes K.S., Simon R., Songhorabodi S., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100 (1986) 2782-2784
6. Nordlinger B., Quilichini M.A., Parc R., Hannoun L., Delva E., and Huguet C. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 205 (1987) 256-263
7. Scheele J., Stang R., Altendorf-Hofmann A., and Paul M. Resection of colorectal liver metastases. World J Surg 19 (1995) 59-71
8. Hosch S.B., Steffani K.D., Scheunemann P., and Izbicki J.R. Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 9 (2002) 583-591
9. Yokoyama N., Shirai Y., Ajioka Y., Nagakura S., Suda T., and Hatakeyama K. Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 94 (2002) 1642-1647
10. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 (1996) 1254-1262
11. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
12. Smith D.L., Soria J.C., Morat L., et al. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 11 (2004) 45-51
13. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
14. Smith G., Carey F.A., Beattie J., et al. Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99 (2002) 9433-9438
15. Olschwang S., Hamelin R., Laurent-Puig P., et al. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA 94 (1997) 12122-12127
16. Tomlinson I., Ilyas M., Johnson V., et al. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer. J Pathol 184 (1998) 148-152
17. Kahlenberg M.S., Sullivan J.M., Witmer D.D., and Petrelli N.J. Molecular prognostics in colorectal cancer. Surg Oncol 12 (2003) 173-186
18. Graziano F., and Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann Oncol 14 (2003) 1026-1038
19. Anwar S., Frayling I.M., Scott N.A., and Carlson G.L. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 91 (2004) 1275-1291
20. Aschele C., Debernardis D., Tunesi G., Maley F., and Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6 (2000) 4797-4802
21. Backus H.H., Van Groeningen C.J., Vos W., et al. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55 (2002) 206-211
22. Agui T., McConkey D.J., and Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 22 (2002) 1769-1776
23. Scartozzi M., Bearzi I., Berardi R., Mandolesi A., Fabris G., and Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. Clin Oncol 22 (2004) 4772-4778
24. Kelloff G.J., Boone C.W., Steele V.E., Crowell J.A., Lubet R., and Sigman C.C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54 (1994) S2015-S2024
25. Srinivas P.R., Kramer B.S., and Srivastava S. Trends in biomarker research for cancer detection. Lancet Onc 2 (2001) 698-704
26. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 47 (2001) 624-630
27. Rommel C., and Hafen E. Ras - a versatile cellular switch. Curr Opin Genet Dev 8 (1998) 412-418
28. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
29. Barbacid M. ras genes. Annu Rev Biochem 56 (1987) 779-827
30. Shirasawa S., Furuse M., Yokoyama N., and Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260 (1993) 85-88
31. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., and Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90 (1998) 675-684
32. Andreyev H.J., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85 (2001) 692-696
33. Bazan V., Migliavacca M., Zanna I., et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13 (2002) 1438-1446
34. Font A., Abad A., Monzo M., et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44 (2001) 549-557
35. Russo A., Migliavacca M., Bazan V., et al. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif 31 (1998) 139-153
36. Kastrinakis W.V., Ramchurren N., Maggard M., Steele Jr. G., and Summerhayes I.C. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 130 (1995) 9-14
37. Petrowsky H., Sturm I., Graubitz O., et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27 (2001) 80-87
38. Crowe P.J., Yang J.L., Berney C.R., et al. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 25 (2001) 996-1001
39. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 (2001) S9-S15
40. Lee J.C., Wang S.T., Chow N.H., and Yang H.B. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38 (2002) 1065-1071
41. De Jong K.P., Stellema R., Karrenbeld A., et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28 (1998) 971-979
42. Gonen M., Hummer A., Zervoudakis A., et al. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21 (2003) 406-412
43. Rodrigues N.R., Rowan A., Smith M.E., et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87 (1990) 7555-7559
44. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
45. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
46. Kang S.M., Maeda K., Onoda N., et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74 (1997) 502-507
47. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 59 (1994) 483-489
48. Sory A., Minamoto T., Ohta T., et al. Does p53 overexpression cause metastases in early invasive colorectal adenocarcinoma?. Eur J Surg 163 (1997) 685-692
49. Tullo A., D'Erchia A.M., Honda K., et al. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clin Cancer Res 5 (1999) 3523-3528
50. Jenkins J.R., Rudge K., Chumakov P., and Currie G.A. The cellular oncogene p53 can be activated by mutagenesis. Nature 317 (1985) 816-818
51. Baas I.O., Mulder J.W., Offerhaus G.J., Vogelstein B., and Hamilton S.R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172 (1994) 5-12
52. Soong R., Grieu F., Robbins P., et al. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3 (1997) 1405-1411
53. Kahlenberg M.S., Stoler D.L., Rodriguez-Bigas M.A., et al. p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88 (2000) 1814-1819
54. Petersen S., Thames H.D., Nieder C., Petersen C., and Baumann M. The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 44 (2001) 322-333
55. Costa A., Doci R., Mochen C., et al. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. Clin Oncol 15 (1997) 2008-2014
56. Pocard M., Paradis V., Adam R., Reynes M., and Bismuth H. Possible prognostic significance of p53 immunoreactive status of hepatic colorectal cancer metastases following surgical resection. Eur J Cancer 34 (1998) 594-595
57. Nitti D., Belluco C., Montesco M.C., et al. Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. Eur J Cancer 34 (1998) 851-855
58. Heisterkamp J., van Bommel J., Hop W.C., Tilanus H.W., Zondervan P.E., and Ijzermans J.N. P53 overexpression in colorectal metastases confined to the liver and outcome of liver resection. Hepatogastroenterology 46 (1999) 3109-3114
59. Sturm I., Kohne C.H., Wolff G., et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17 (1999) 1364-1374
60. Yang Y., Forslund A., Remotti H., et al. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91 (2001) 727-736
61. Saw R.P., Koorey D., Painter D., Gallagher P.J., and Solomon M.J. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 89 (2002) 1409-1415
62. Tanaka K., Shimada H., Miura M., et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 28 (2004) 263-270
63. De Jong K.P., Gouw A.S., Peeters P.M., et al. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11 (2005) 4067-4073
64. Brenner D.A. Signal transduction during liver regeneration. J Gastroenterol Hepatol 13 (1998) S93-S95
65. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88 (1996) 1442-1455
66. Dix B., Robbins P., Carrello S., House A., and Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 70 (1994) 585-590
67. Cripps K.J., Purdie C.A., Carder P.J., et al. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9 (1994) 2739-2743
68. Lane D.P. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 57 (1994) 623-627
69. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
70. Soussi T., and Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1 (2001) 233-240
71. Borresen-Dale A.L., Lothe R.A., Meling G.I., Hainaut P., Rognum T.O., and Skovlund E. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4 (1998) 203-210
72. Harper J.W., Elledge S.J., Keyomarsi K., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6 (1995) 387-400
73. Zirbes T.K., Baldus S.E., Moenig S.P., et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 89 (2000) 14-18
74. Ookawa K., Sakamoto M., Hirohashi S., et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 53 (1993) 382-387
75. Jen J., Kim H., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 (1994) 213-221
76. Ogunbiyi O.A., Goodfellow P.J., Herfarth K., et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16 (1998) 427-433
77. Fearon E.R. DCC: is there a connection between tumorigenesis and cell guidance molecules?. Biochim Biophys Acta 1288 (1996) 17-23
78. Reymond M.A., Dworak O., Remke S., Hohenberger W., Kirchner T., and Kockerling F. DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 41 (1998) 755-760
79. Shibata D., Reale M.A., Lavin P., et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 335 (1996) 1727-1732
80. Eppert K., Scherer S.W., Ozcelik H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86 (1996) 543-552
81. Hahn S.A., Schutte M., Hoque A.T., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21. Science 271 (1996) 350-353
82. Miyaki M., Iijima T., Konishi M., et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18 (1999) 3098-3103
83. Kochhar R., Halling K.C., McDonnell S., et al. Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol 6 (1997) 78-84
84. Aschele C., Debernardis D., Lonardi S., et al. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. J Clin Oncol 22 (2004) 3758-3765
85. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Dambaki K., Niniraki M., and Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 27 (2004) 8-13
86. Michels J.J., Marnay J., Delozier T., Denoux Y., and Chasle J. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 100 (2004) 455-464
87. Kontogianni K., Demonakou M., Kavantzas N., et al. Prognostic predictors of gastrointestinal stromal tumors: a multi-institutional analysis of 102 patients with definition of a prognostic index. Eur J Surg Oncol 29 (2003) 548-556
88. Gerdes J., Schwab U., Lemke H., and Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31 (1983) 13-20
89. Key G., Becker M.H., Baron B., et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68 (1993) 629-636
90. Tan C.K., Castillo C., So A.G., and Downey K.M. An auxiliary protein for DNA polymerase-delta from fetal calf thymus. J Biol Chem 261 (1986) 12310-12316
91. Witzig T.E., Loprinzi C.L., Gonchoroff N.J., et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68 (1991) 879-888
92. Pietra N., Sarli L., Sansebastiano G., Jotti G.S., and Peracchia A. Prognostic value of ploidy, cell proliferation kinetics, and conventional clinicopathologic criteria in patients with colorectal carcinoma: a prospective study. Dis Colon Rectum 39 (1996) 494-503
93. Allegra C.J., Parr A.L., Wold L.E., et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20 (2002) 1735-1743
94. Jansson A., and Sun X.F. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 105 (1997) 730-734
95. Sun X.F., Carstensen J.M., Stal O., Zhang H., and Nordenskjold B. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer 69 (1996) 5-8
96. Palmqvist R., Sellberg P., Oberg A., Tavelin B., Rutegard J.N., and Stenling R. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 79 (1999) 577-581
97. Garrity M.M., Burgart L.J., Mahoney M.R., et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 22 (2004) 1572-1582
98. Palmqvist R., Oberg A., Bergstrom C., et al. Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer 77 (1998) 917-925
99. Nanashima A., Yamaguchi H., Shibasaki S., et al. Proliferation of hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 14 (1999) 61-66
100. Weber J.C., Nakano H., Bachellier P., et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?. Am J Surg 182 (2001) 81-88
101. Onodera H., Mori A., Nagayama S., et al. Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer. Int J Colorectal Dis 20 (2005) 477-484
102. Koga H., Moriya Y., Akasu T., and Fujita S. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 25 (1999) 292-296
103. Warshaw A.L., and Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 326 (1992) 455-465
104. Balcom IV J.H., Keck T., Warshaw A.L., et al. Telomerase activity in periampullary tumors correlates with aggressive malignancy. Ann Surg 234 (2001) 344-350
105. Domont J., Pawlik T.M., Boige V., et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 23 (2005) 3086-3093
106. Danenberg P.V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473 (1977) 73-92
107. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. Clin Oncol 22 (2004) 529-536
108. Johnston P.G., Drake J.C., Trepel J., and Allegra C.J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52 (1992) 4306-4312
109. Peters G.J., van der Wilt C.L., van Triest B., et al. Thymidylate synthase and drug resistance. Eur J Cancer 31 (1995) 1299-1305
110. Edler D., Hallstrom M., Johnston P.G., Magnusson I., Ragnhammar P., and Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6 (2000) 1378-1384
111. Yamachika T., Nakanishi H., Inada K., et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82 (1998) 70-77
112. Derenzini M., Montanaro L., Trere D., et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 55 (2002) 310-314
113. Edler D., Hallstrom M., Ragnhammar P., and Blomgren H. Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression. Anticancer Res 22 (2002) 3113-3116
114. Chu E., Voeller D.M., Jones K.L., et al. Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol Cell Biol 14 (1994) 207-213
115. Ju J., Pedersen-Lane J., Maley F., and Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 96 (1999) 3769-3774
116. Bathe O.F., Franceschi D., Livingstone A.S., Moffat F.L., Tian E., and Ardalan B. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5 (1999) 34-40
117. Corsi D.C., Ciaparrone M., Zannoni G., et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 38 (2002) 527-534
118. Giatromanolaki A., Stathopoulos G.P., Tsiobanou E., et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86 (1999) 1421-1430
119. Gross A., McDonnell T.J., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13 (1999) 1899-1911
120. Ried T., Heselmeyer-Haddad K., Blegen H., Schrock E., and Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 25 (1999) 195-204
121. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
122. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instability in colorectal cancers. Nature 386 (1997) 623-627
123. Shih I.M., Zhou W., Goodman S.N., Lengauer C., Kinzler K.W., and Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61 (2001) 818-822
124. Jallepalli P.V., and Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer 1 (2001) 109-117
125. Fodde R., Kuipers J., Rosenberg C., et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3 (2001) 433-438
126. Loeb L.A. A mutator phenotype in cancer. Cancer Res 61 (2001) 3230-3239
127. Jones D.J., Moore M., and Schofield P.F. Prognostic significance of DNA ploidy in colorectal cancer: a prospective flow cytometric study. Br J Surg 75 (1988) 28-33
128. Chapman M.A., Hardcastle J.D., and Armitage N.C. Five-year prospective study of DNA tumor ploidy and colorectal cancer survival. Cancer 76 (1995) 383-387
129. Bazan V., Migliavacca M., Zanna I., et al. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol 128 (2002) 650-658
130. Russo A., Migliavacca M., Zanna I., et al. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. Cancer Epidemiol Biomarkers Prev 11 (2002) 1322-1331
131. Cady B., Stone M.D., McDermott Jr. W.V., et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 127 (1992) 561-568
132. Tsushima K., Nagorney D.M., Rainwater L.M., et al. Prognostic significance of nuclear deoxyribonucleic acid ploidy patterns in resected hepatic metastases from colorectal carcinoma. Surgery 102 (1987) 635-643
133. Lind D.S., Parker G.A., Horsley III J.S., et al. Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis. Ann Surg 215 (1992) 677-683
134. Yamaguchi A., Kurosaka Y., Kanno M., et al. Analysis of hepatic recurrence of colorectal cancer after resection of hepatic metastases. Int Surg 78 (1993) 16-19
135. Cady B., Jenkins R.L., Steele Jr. G.D., et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227 (1998) 566-571
136. Cosimelli M., D'Agnano I., Tedesco M., et al. The role of multiploidy as unfavorable prognostic variable in colorectal cancer. Anticancer Res 18 (1998) 1957-1965
137. Kinzler K.W., and Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386 (1997) 761-763
138. Cunningham J.M., Christensen E.R., Tester D.J., et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58 (1998) 3455-3460
139. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
140. Haddad R., Ogilvie R.T., Croitoru M., et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol 11 (2004) 977-982
141. Mehta K.R., Nakao K., Zuraek M.B., et al. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res 11 (2005) 1791-1797
142. Goel A., Arnold C.N., Niedzwiecki D., et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63 (2003) 1608-1614
143. Tang R., Changchien C.R., Wu M.C., et al. Colorectal cancer without high microsatellite instability and chromosomal instability - an alternative genetic pathway to human colorectal cancer. Carcinogenesis 25 (2004) 841-846
144. Nakao K., Mehta K.R., Fridlyand J., et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 25 (2004) 1345-1357
145. Douglas E.J., Fiegler H., Rowan A., et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 64 (2004) 4817-4825
146. Jones A.M., Douglas E.J., Halford S.E., et al. Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 24 (2005) 118-129
147. De Angelis P.M., Stokke T., Beigi M., Mjaland O., and Clausen O.P. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int J Colorectal Dis 16 (2001) 38-45
148. Cahill D.P., Kinzler K.W., Vogelstein B., and Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9 (1999) M57-M60
149. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
150. Fontanini G., Bigini D., Vignati S., et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177 (1995) 57-63
151. Fontanini G., Vignati S., Pacini F., Pollina L., and Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol 9 (1996) 636-641
152. Tomisaki S., Ohno S., Ichiyoshi Y., Kuwano H., Maehara Y., and Sugimachi K. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 77 (1996) 1722-1728
153. Takebayashi Y., Aklyama S., Yamada K., Akiba S., and Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 78 (1996) 226-231
154. Abdalla S.A., Behzad F., Bsharah S., et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 6 (1999) 839-842
155. Prall F., Gringmuth U., Nizze H., and Barten M. Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 42 (2003) 482-491
156. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G., and Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55 (1995) 5049-5053
157. Pavlopoulos P.M., Konstantinidou A.E., Agapitos E., Kavantzas N., Nikolopoulou P., and Davaris P. A morphometric study of neovascularization in colorectal carcinoma. Cancer 83 (1998) 2067-2075
158. Nanashima A., Ito M., Sekine I., et al. Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers. Dig Dis Sci 43 (1998) 2634-2640
159. Nanashima A., Yamaguchi H., Sawai T., et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci 46 (2001) 1623-1628
160. Miyagawa S., Miwa S., Soeda J., Kobayashi A., and Kawasaki S. Morphometric analysis of liver macrophages in patients with colorectal liver metastasis. Clin Exp Metastasis 19 (2002) 119-125
161. Martin L., Green B., Renshaw C., et al. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 76 (1997) 1046-1054
162. Trojan L., Thomas D., Friedrich D., et al. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation. Anticancer Res 24 (2004) 1651-1656
163. Sutton C.D., Marshall L.J., Goddard J.C., et al. Biological factors influencing angiogenesis and prognosis in resected colorectal liver metastases. Br J Surg 91 Suppl. 1 (2004) 30
164. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 2 (1996) 167-168
165. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
166. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., and Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 (1995) 3964-3968
167. Ishigami S.I., Arii S., Furutani M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78 (1998) 1379-1384
168. Berney C.R., Yang J.L., Fisher R.J., Russell P.J., and Crowe P.J. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 18 (1998) 973-977
169. Lawler J. The structural and functional properties of thrombospondin. Blood 67 (1986) 1197-2209
170. Maeda K., Nishiguchi Y., Kang S.M., et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 8 (2001) 763-766
171. Sutton C.D., O'Byrne K., Goddard J.C., et al. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin Cancer Res 11 (2005) 6567-6573
172. Dorudi S., Sheffield J.P., Poulsom R., Northover J.M., and Hart I.R. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 142 (1993) 981-986
173. Koretz K., Moller P., Lehnert T., Hinz U., Otto H.F., and Herfarth C. Effect of CD44v6 on survival in colorectal carcinoma. Lancet 345 (1995) 327-328
174. Nanashima A., Yamaguchi H., Sawai T., et al. Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 14 (1999) 1004-1009
175. Howlett A.R., Petersen O.W., Steeg P.S., and Bissell M.J. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 86 (1994) 1838-1844
176. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 (1997) 1260-1270
177. Waas E.T., Wobbes T., Lomme R.M., DeGroot J., Ruers T., and Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 90 (2003) 1556-1564
178. Benhattar J., Cerottini J.P., Saraga E., Metthez G., and Givel J.C. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69 (1996) 190-192
179. Backus H.H., van Riel J.M., van Groeningen C.J., et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12 (2001) 779-785
180. Aschele C., Debernardis D., Casazza S., et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17 (1999) 1760-1770
181. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
182. Bertucci F., Salas S., Eysteries S., et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23 (2004) 1377-1391
183. D'Arrigo A., Belluco C., Ambrosi A., et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 115 (2005) 256-262